AKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
PR Newswire
NEW ORLEANS, May 3, 2024
NEW ORLEANS, May 3, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 25, 2024 to file lead plaintiff applications in a securities class action lawsuit against Akero Therapeutics, Inc. (NasdaqGS: AKRO), if they purchased or otherwise acquired the Company's shares between September 13, 2022 and October 9, 2023, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of California.
Get Help
Akero Therapeutics investors should visit us at https://claimsfiler.com/cases/nasdaq-akro/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
About the Lawsuit
Akero and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) approximately 20% of patients enrolled in the SYMMETRY study for the Company's lead product candidate efruxifermin ("EFX") had cryptogenic cirrhosis (and did not have definitive nonalcoholic steatohepatitis ("NASH"), a serious liver disease), at baseline; (ii) the cryptogenic cirrhotic patients included in the SYMMETRY study did not have biopsy-proven compensated cirrhosis due to definitive NASH; (iii) the results from the cryptogenic cirrhosis patients were to be excluded from the calculation of the NASH resolution secondary endpoints; (iv) the Company had introduced a confounding factor into the SYMMETRY study's design, materially influencing the study's potential results and increasing the risks that the study would fail to meet its primary endpoint; (v) the SYMMETRY study did not align with U.S. Food & Drug Administration guidance for testing a drug in treating NASH cirrhotics because Akero had not ruled out potential causes of each patient's cirrhosis other than NASH; and (vi) consequently, the Company had materially misrepresented the nature of the SYMMETRY trial, its usefulness in supporting any new drug application, the likelihood that the SYMMETRY trial would be successful as measured by its primary endpoint, and the likelihood that EFX would become a commercial treatment for NASH cirrhotics.
The market finally began to learn the truth on October 10, 2023, pre-market, when the Company disclosed the study's 36-week results, causing the price of Akero's stock to fall $30.39 per share on October 10, 2023 and $3.11 per share on October 11, 2023 on higher than average volume – a decline of nearly 70% from the stock's closing price of $48.54 per share on October 9, 2023.
The case is Klobus v. Akero Therapeutics, Inc., No. 24-cv-02534.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
View original content:SOURCE ClaimsFiler
